If there's one thing we can all agree upon, it's that the 21st century's captains of industry are trying to shoehorn AI into every corner of our world. But for all of the ways in which AI will be shoved into our faces and not prove very successful, it might actually have at least one useful purpose. Risk mitigation isn't a sexy notion but it's worth understanding how common it is for a new drug project to fail. To set the scene, consider that each drug project takes between three and five years to form a hypothesis strong enough to start tests in a laboratory. A 2022 study from Professor Duxin Sun found that 90 percent of clinical drug development fails, with each project costing more than 2 billion.

To battle the novel coronavirus that's been linked to Wuhan, China, researchers are using artificial intelligence to discover potential treatments, including already-approved drugs and completely new compounds. At the same time, the pneumonia-like illness has only gotten worse. As of Friday morning, the 2019-nCoV coronavirus had taken the lives of more than 600 people and infected more than 30,000, with cases documented in at least 25 countries. Researchers at the British artificial intelligence startup Benevolent AI say they used the tech to search for existing approved drugs that might be helpful in limiting the virus's infection. Another set of scientists affiliated with Deargen, a drug discovery company based in South Korea, say that they used deep learning to find various available antiviral drugs that could be investigated as a potential treatment (that research has not yet been peer-reviewed). Meanwhile, a Maryland-based biotech company, Insilico, said it used AI to come up with new molecules that could serve as potential medications, and it will now synthesize and test 100 of the compounds, according to Fortune.

Artificial intelligence has now become the focus of interest in most business areas. It is because in the past few years technological applications have compounded in terms of innovations and research. What failed in the late '50s (the period when AI originated) has now gained traction and is used in a vast array of areas. Tech companies and startups have now focussed on AI systems being their workhorse in tandem with their employees and have reinvented the way work is done. Additionally, AI startups are also on the rise.

Artificial intelligence robots are turbocharging the race to find new drugs for the crippling nerve disorder ALS, commonly called Lou Gehrig's disease. The condition attacks and kills nerve cells controlling muscles, leading to weakness, paralysis and, ultimately, respiratory failure. There are only two drugs approved by the U.S. Food and Drug Administration to slow the progression of ALS (amyotrophic lateral sclerosis), one available since 1995 and the other approved just this year. About 140,000 new cases are diagnosed a year globally, and there is no cure. "Many doctors call it the worst disease in medicine, and the unmet need is huge," said Richard Mead of the Sheffield Institute of Translational Neuroscience, who has found artificial intelligence (AI) is already speeding up his work.

LONDON (Reuters) - Artificial intelligence robots are turbo-charging the race to find new drugs for the crippling nerve disorder ALS, or motor neurone disease. The condition, also known as Lou Gehrig's disease, attacks and kills nerve cells controlling muscles, leading to weakness, paralysis and, ultimately, respiratory failure. There are only two drugs approved by the U.S. Food and Drug Administration to slow the progression of ALS (amyotrophic lateral sclerosis), one available since 1995 and the other approved just this year. About 140,000 new cases are diagnosed a year globally and there is no cure for the disease, famously suffered by cosmologist Stephen Hawking. "Many doctors call it the worst disease in medicine and the unmet need is huge," said Richard Mead of the Sheffield Institute of Translational Neuroscience, who has found artificial intelligence (AI) is already speeding up his work. They analyze huge chemical, biological and medical databases, alongside reams of scientific papers, far quicker than humanly possible, throwing up new biological targets and potential drugs.

While only parts of the original ban are currently in effect, the president and his minions have damaged the United States' reputation as a place that welcomes scientists, engineers, and technologists (and admittedly, pretty much everyone else in the world). In May, a coalition of academic and educational groups raised concerns about plans for "enhanced vetting," writing in a letter to the State Department, "We are very concerned that if the proposed changes are implemented, international undergraduate and graduate students, scholars, and scientific collaborators may be discouraged from coming to the United States." A March report said that 40 percent of colleges had seen declines in applications from international students.

London-based biotech business BenevolentBio is on a mission to overcome the failure of the drug industry to innovate on drug discovery. Andrew Huddart explains and talks to its chief executive, Jackie Hunter. The tools of big data are helping to reshape the industrial landscape of the 21st century. They are helping make entire economic activities obsolete and helping give rise to new ones. The area of health and drug discovery in particular is far from excluded from this change.

New drugs typically take 12-14 years to make it to market, with a 2014 report finding that the average cost of getting a new drug to market had ballooned to a whopping 2.6 billion. It's a topic I've covered before, with a study published earlier this year highlighting how automation could be used to reduce the cost of drug discovery by approximately 70%. It's an approach that a number of companies are taking to market. For instance, London based start-up Benevolent.AI utilizes complex AI to look for patterns in the scientific literature. They have already managed to identify two potential drug targets for Alzheimer's that has already attracted the attention of pharmaceutical companies.